Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Metrics to compare | TCF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCFPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −6.0x | −0.5x | |
PEG Ratio | −0.04 | −0.05 | 0.00 | |
Price/Book | 0.8x | 5.0x | 2.6x | |
Price / LTM Sales | - | 13.8x | 3.3x | |
Upside (Analyst Target) | - | 88.9% | 41.6% | |
Fair Value Upside | Unlock | −13.4% | 5.9% | Unlock |